PMVP on Nasdaq
PMV Pharmaceuticals, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $69.9M | $58.5M | $55.9M |
| General and administrative | $16.3M | $26.9M | $24.2M |
| Total operating expenses | $86.2M | $85.4M | $80.1M |
| Loss from operations | -$86.2M | -$85.4M | -$80.1M |
| Interest income, net | $6.3M | $10.7M | $11.2M |
| Other (expense) income, net | -$45.0K | -$16.0K | $3.0K |
| Total other income | $6.3M | $10.6M | $11.2M |
| Loss before provision (benefit) for income taxes | -$79.9M | -$74.8M | -$69.0M |
| Provision (benefit) for income taxes | -$2.2M | -$16.1M | $2.0K |
| Net loss | -$77.7M | -$58.7M | -$69.0M |
| Unrealized (loss) gain on available for sale investments, net of tax | -$63.0K | -$50.0K | $635.0K |
| Foreign currency translation gain (loss) gain | $8.0K | -$35.0K | $34.0K |
| Total other comprehensive (loss) income | -$55.0K | -$85.0K | $669.0K |
| Total Comprehensive loss | -$77.8M | -$58.8M | -$68.3M |
| Net loss per share - basic | -$1.48 | -$1.14 | -$1.44 |
| Net loss per share - diluted | -$1.48 | -$1.14 | -$1.44 |
| Weighted-average common shares outstanding - basic | 52.5M shares | 51.6M shares | 48.0M shares |
| Weighted-average common shares outstanding - diluted | 52.5M shares | 51.6M shares | 48.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $38.0M | $40.9M | ||
| Marketable securities, current | $75.0M | $128.6M | ||
| Prepaid expenses and other current assets | $2.3M | $6.2M | ||
| Total current assets | $115.2M | $175.7M | ||
| Property and equipment, net | $237.0K | $409.0K | ||
| Marketable securities, noncurrent | $0 | $13.8M | ||
| Right-of-use assets | $801.0K | $1.1M | ||
| Other assets | $297.0K | $235.0K | ||
| Total assets | $116.6M | $191.3M | ||
| Accounts payable | $3.2M | $6.6M | ||
| Accrued expenses | $7.9M | $7.4M | ||
| Operating lease liabilities, current | $403.0K | $352.0K | ||
| Total current liabilities | $11.4M | $14.4M | ||
| Operating lease liabilities, noncurrent | $435.0K | $838.0K | ||
| Total liabilities | $11.8M | $15.2M | ||
| Additional paid-in capital | $551.1M | $544.7M | ||
| Accumulated deficit | -$446.5M | -$368.7M | ||
| Accumulated other comprehensive income | $84.0K | $139.0K | ||
| Total stockholders' equity | $104.7M | $176.1M | $225.7M | $246.0M |
| Total liabilities and stockholders equity | $116.6M | $191.3M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 1.0B shares | 1.0B shares | ||
| Common stock, shares issued | 53.3M shares | 51.9M shares | ||
| Common stock, shares outstanding | 53.3M shares | 51.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $38.0M | $40.9M | ||
| Marketable securities, current | $75.0M | $128.6M | ||
| Prepaid expenses and other current assets | $2.3M | $6.2M | ||
| Total current assets | $115.2M | $175.7M | ||
| Property and equipment, net | $237.0K | $409.0K | ||
| Marketable securities, noncurrent | $0 | $13.8M | ||
| Right-of-use assets | $801.0K | $1.1M | ||
| Other assets | $297.0K | $235.0K | ||
| Total assets | $116.6M | $191.3M | ||
| Accounts payable | $3.2M | $6.6M | ||
| Accrued expenses | $7.9M | $7.4M | ||
| Operating lease liabilities, current | $403.0K | $352.0K | ||
| Total current liabilities | $11.4M | $14.4M | ||
| Operating lease liabilities, noncurrent | $435.0K | $838.0K | ||
| Total liabilities | $11.8M | $15.2M | ||
| Additional paid-in capital | $551.1M | $544.7M | ||
| Accumulated deficit | -$446.5M | -$368.7M | ||
| Accumulated other comprehensive income | $84.0K | $139.0K | ||
| Total stockholders' equity | $104.7M | $176.1M | $225.7M | $246.0M |
| Total liabilities and stockholders equity | $116.6M | $191.3M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 1.0B shares | 1.0B shares | ||
| Common stock, shares issued | 53.3M shares | 51.9M shares | ||
| Common stock, shares outstanding | 53.3M shares | 51.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$77.7M | -$58.7M | -$69.0M |
| Stock-based compensation expense | $5.9M | $8.9M | $12.4M |
| Depreciation | $133.0K | $1.1M | $1.3M |
| Accretion of discounts on marketable securities | -$2.8M | -$5.4M | -$5.4M |
| Non-cash lease income | -$10.0K | -$248.0K | -$370.0K |
| Loss on termination of lease, net | $4.6M | ||
| Loss on sales and disposals of fixed assets, net | $37.0K | $62.0K | |
| Other, net | -$62.0K | -$44.0K | |
| Prepaid expenses and other assets | $3.9M | -$2.7M | $1.7M |
| Operating lease right-of-use assets and liabilities | $241.0K | $837.0K | |
| Accounts payable | -$3.4M | $3.3M | $235.0K |
| Accrued expenses | $418.0K | -$2.5M | $2.6M |
| Net cash used in operating activities | -$73.6M | -$51.3M | -$55.7M |
| Purchases of property and equipment | -$29.0K | -$655.0K | -$962.0K |
| Proceeds from sale of property and equipment | $31.0K | $251.0K | |
| Purchases of marketable securities | -$88.2M | -$148.3M | -$220.5M |
| Maturities of marketable securities | $158.4M | $202.0M | $171.0M |
| Net cash provided by investing activities | $70.2M | $53.4M | -$50.5M |
| Issuance of common stock, net of issuance costs | $35.1M | ||
| Proceeds from the exercise of stock options and common stock issued under the 2020 EIP | $505.0K | $313.0K | $456.0K |
| Net cash provided by financing activities | $505.0K | $313.0K | $35.6M |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | $7.0K | -$35.0K | $34.0K |
| Net (decrease) increase in cash and cash equivalents | -$2.9M | $2.3M | -$70.6M |
| Accrued purchases of property and equipment | $6.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led PMV Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerDavid Henry Mack Sep 24, 2020 to now11
- PresidentDavid Henry Mack Sep 24, 2020 to now11
- Chief financial officerMichael Carulli Jan 11, 2024 to now12
- Chief financial officerWinston Kung Sep 24, 2020 to May 15, 202313
- Chief operating officerRobert Ticktin Apr 23, 2025 to now14
- Chief operating officerWinston Kung Sep 24, 2020 to May 15, 202313
Board members and other officers (13)
- SVP, Regulatory Affairs and QADeepika Jalota Sep 24, 2020 to now15
- Chief Medical OfficerLeila Alland Sep 24, 2020 to Sep 18, 202316
- Board memberKirsten Flowers Jan 10, 2022 to now17
- Board memberCarol Giltner Gallagher Nov 8, 2022 to now18
- Board memberCharles M. Baum Apr 7, 2021 to now19
- Board memberArnold J. Levine Sep 24, 2020 to now20
- Board memberArnold L. Oronsky Sep 24, 2020 to Oct 2, 202021
- Board memberDavid Henry Mack Sep 24, 2020 to now11
- Board memberLaurie Stelzer Sep 24, 2020 to now22
- Board memberPeter A. Thompson Sep 24, 2020 to Jun 9, 202123
- Board memberRichard A. Heyman Sep 24, 2020 to now24
- Board memberThilo Schroeder Sep 24, 2020 to Oct 8, 202125
- General counselRobert Ticktin Apr 23, 2025 to now14
Timeline
- Sep 24, 2020New chief executive David Henry Mack becomes CEO11
Filings
241 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 39 major events, 84 insider forms, 62 large holders, 36 other. The latest 20:
- Oct 5, 20264 EDGAR
- Oct 5, 20263 EDGAR
- Oct 5, 20268-K EDGAR
- Sep 15, 2026SCHEDULE 13G EDGAR
- Sep 2, 20268-K EDGAR
- Sep 2, 2026424B5 EDGAR
- Aug 31, 2026424B3 EDGAR
- Aug 31, 2026424B5 EDGAR
- Aug 31, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 14, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 10, 2026SCHEDULE 13G/A EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20268-K EDGAR
- Jun 5, 20264 EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
The 241 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 62 such filings since October 2021, the latest 10:
- Sep 15, 2026SCHEDULE 13G
- Jul 28, 2026SCHEDULE 13G/A
- Jul 10, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 4, 2026SCHEDULE 13G/A
- Mar 4, 2026SCHEDULE 13D/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 9, 2026SCHEDULE 13G/A
- Nov 12, 2025SCHEDULE 13G/A
- Oct 27, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 64. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BML Capital Management, LLC | 5,330,000 | $7.1M | 4.1% | +10,000 |
| Tang Capital Management LLC | 4,245,085 | $5.7M | 0.3% | No change |
| Sio Capital Management, LLC | 2,634,137 | $3.5M | 0.6% | −442,443 |
| Euclidean Capital LLC | 2,627,643 | $3.5M | 0.8% | No change |
| Adage Capital Partners Gp, L.l.c. | 2,360,000 | $3.2M | 0.0% | +500,000 |
| Vanguard Capital Management LLC | 2,012,020 | $2.7M | 0.0% | +37,114 |
| ArrowMark Colorado Holdings LLC | 1,959,579 | $2.6M | 0.1% | −913,185 |
| Two Sigma Investments, LP | 1,954,136 | $2.6M | 0.0% | +69,606 |
| Eversept Partners, LP | 1,890,904 | $2.5M | 0.1% | −457,456 |
| BlackRock, Inc. | 919,818 | $1.2M | 0.0% | +45,444 |
| Assenagon Asset Management S.A. | 660,006 | $884.4K | 0.0% | +299,220 |
| Stonepine Capital Management, LLC | 536,086 | $718.4K | 0.5% | −172,016 |
| Geode Capital Management, LLC | 473,158 | $634.6K | 0.0% | −22,764 |
| Aldebaran Capital, LLC | 467,432 | $626.4K | 0.5% | −5,930 |
| Bridgeway Capital Management, LLC | 428,853 | $574.7K | 0.0% | No change |
| BIT Capital GmbH | 407,555 | $546.1K | 0.0% | +284,000 |
| Verdad Advisers, LP | 362,361 | $485.6K | 0.5% | +182,200 |
| Walleye Capital LLC | 335,694 | $449.8K | 0.0% | No change |
| Marshall Wace, Llp | 321,610 | $431.0K | 0.0% | −112,483 |
| Vanguard Fiduciary Trust Co | 254,775 | $341.4K | 0.0% | −43,351 |
| Bank Of America Corp /de/ | 240,110 | $321.7K | 0.0% | −421 |
| ADAR1 Capital Management, LLC | 201,008 | $269.4K | 0.0% | −30,000 |
| State Street Corp | 183,178 | $245.5K | 0.0% | No change |
| RBF Capital, LLC | 162,200 | $217.3K | 0.0% | No change |
| Goldman Sachs Group Inc | 136,994 | $183.6K | 0.0% | +22,130 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARLeila Alland, Chief Medical Officer
- 17SEC EDGARKirsten Flowers, Board member
- 18
- 19SEC EDGARCharles M. Baum, Board member
- 20SEC EDGARArnold J. Levine, Board member
- 21SEC EDGARArnold L. Oronsky, Board member
- 22SEC EDGARLaurie Stelzer, Board member
- 23SEC EDGARPeter A. Thompson, Board member
- 24SEC EDGARRichard A. Heyman, Board member
- 25SEC EDGARThilo Schroeder, Board member